GSK raises $1.5 bln from sale of remaining Haleon stake
The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley’s plans to boost earnings at the drugmaker.
If you are not happy with the results below please do another search
The sale will allow GSK to sharpen its focus on vaccines, cancer and infectious diseases, which are part of CEO Emma Walmsley’s plans to boost earnings at the drugmaker.
The drug, marketed under the name Imdelltra, is part of Amgen’s pipeline of bispecific antibodies designed to attach to a cancer cell and an immune cell, bringing them together so that the body’s immune system can kill the cancer.
“If women aren’t in decision-making roles, then the best decisions won’t always be made,” declared Healthcare Businesswomen’s Association’s (HBA) CEO Mary Stutts. “If our workplaces are not inclusive and representative of our patient populations, health equity will never become a reality.” Stutts opened the HBA’s annual Woman of the Year program with a call to action for the professionals in the room as well as the broader industry. “We all share the moral and ethical responsibility, as well as the financial obligation, to do better. We’re in a new era.”
Following back-to-back approvals in lymphocytic leukemia, Bristol Myers Squibb’s CAR-T therapy Breyanzi on Wednesday won the FDA’s green light for relapsed or refractory follicular lymphoma.
Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational GLP-1/GIP receptor agonist induced strong weight loss in a Phase Ib study.
Eli Lilly said its once-weekly insulin injection, efsitora, showed blood sugar reduction that was consistent with commonly used daily insulins across two studies in patients with type 2 diabetes.
J&J looks to gain access to the privately held company’s experimental atopic dermatitis treatments.
The companies announced they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show improvement in patients in an early-to-mid stage study.
EVERSANA INTOUCH has announced a new leader for the medical communications function of the agency. Industry veteran Mary Manna Anderson has joined as the senior VP, managing director, head of medcomm and will oversee both global and U.S. medical communications services as well as future service expansion.
The settlement involves more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday.